GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
T

Town Health International Medical Group 3886.HK · HKD

Health Care · HKEX · 🇭🇰 Hong Kong

Compare

0.17

+2.38%

Close of 9 Nov 2026, in HKD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in HKD, from our data supplier.

FY2025

Revenue

HK$1.79bn

FY2016FY2025

Net income

HK$14.4m

FY2016FY2025

Free cash flow

HK$129.2m

FY2016FY2025

Shareholders' equity

HK$3.00bn

FY2016FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
RevenueHK$1.79bnHK$1.83bnHK$1.83bnHK$1.54bnHK$1.48bnHK$1.07bnHK$1.13bnHK$1.12bnHK$1.11bnHK$1.01bn
Gross profitHK$347.7mHK$487.4mHK$501.9mHK$414.4mHK$471.3mHK$284.6mHK$376.4mHK$372.6mHK$362.0mHK$297.1m
Operating incomeHK$78.8mHK$90.6mHK$102.4mHK$15.3m−HK$7.1m−HK$250.4mHK$68.9mHK$119.9mHK$191.8mHK$26.2m
Net incomeHK$14.4m−HK$203.7m−HK$194.2mHK$15.3mHK$22.0m−HK$281.0mHK$10.5mHK$64.0m−HK$107.7mHK$63.5m
Diluted earnings per share0.00-0.03-0.030.000.00-0.040.000.01-0.010.01

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Total assetsHK$3.95bnHK$4.13bnHK$4.50bnHK$4.75bnHK$4.73bnHK$4.58bnHK$4.74bnHK$4.63bnHK$4.68bnHK$5.16bn
Cash and short-term investmentsHK$1.28bnHK$1.40bnHK$1.20bnHK$1.35bnHK$1.89bnHK$1.82bnHK$1.85bnHK$1.73bnHK$1.47bnHK$1.67bn
Total liabilitiesHK$555.8mHK$746.6mHK$881.8mHK$896.1mHK$504.9mHK$456.5mHK$435.6mHK$289.0mHK$361.0mHK$580.9m
DebtHK$147.6mHK$319.6mHK$456.9mHK$475.0mHK$118.0mHK$139.9mHK$147.5mHK$18.8mHK$19.8mHK$20.8m
Shareholders' equityHK$3.00bnHK$2.98bnHK$3.24bnHK$3.49bnHK$3.86bnHK$3.81bnHK$4.02bnHK$4.07bnHK$4.04bnHK$4.37bn
Shares outstanding6,774m6,774m6,774m7,455m7,526m7,526m7,526m7,526m7,525m7,761m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operationsHK$147.1mHK$244.8mHK$247.5mHK$31.7mHK$170.9mHK$39.1mHK$215.7m−HK$42.4mHK$94.0mHK$420.8m
Capital spending−HK$17.9m−HK$38.7m−HK$17.7m−HK$37.2m−HK$19.9m−HK$35.3m−HK$55.0m−HK$79.7m−HK$82.0m−HK$88.5m
Free cash flowHK$129.2mHK$206.1mHK$229.8m−HK$5.5mHK$151.0mHK$3.8mHK$160.7m−HK$122.0mHK$12.0mHK$332.3m
Dividends paid−HK$8.1m−HK$8.1m−HK$8.1m−HK$11.3m——−HK$18.8m−HK$14.6m−HK$30.8m−HK$85.3m

Latest quarters

By quarter end

Jun 2026Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Sept 2023Jun 2023
RevenueHK$876.4mHK$884.6mHK$900.9mHK$919.5mHK$914.3mHK$916.2mHK$458.1mHK$916.8m
Gross profitHK$225.2mHK$117.5mHK$230.2mHK$237.8mHK$249.6mHK$188.1mHK$129.7mHK$236.8m
Operating incomeHK$35.1mHK$41.0mHK$37.8mHK$35.7mHK$55.0mHK$56.7mHK$30.0mHK$46.7m
Net incomeHK$12.9mHK$1.6mHK$12.7m−HK$156.0m−HK$47.7m−HK$215.3m−HK$107.6mHK$21.1m
Diluted earnings per share0.000.000.00-0.02-0.01-0.03-0.020.00
Cash from operations—HK$99.0mHK$92.0mHK$103.0mHK$159.0mHK$194.0mHK$85.0mHK$100.0m
Capital spending—−HK$8.0m−HK$9.0m−HK$31.0m−HK$7.0m−HK$13.0m−HK$6.0m−HK$3.0m
Free cash flow—HK$91.0mHK$83.0mHK$72.0mHK$152.0mHK$181.0mHK$79.0mHK$97.0m
Total assetsHK$4.04bnHK$3.95bnHK$4.10bnHK$4.13bnHK$4.28bnHK$4.50bnHK$4.50bnHK$4.67bn
Cash and short-term investmentsHK$1.39bnHK$1.28bnHK$1.38bnHK$1.40bnHK$1.16bnHK$1.36bnHK$1.24bnHK$1.13bn
DebtHK$118.8mHK$147.6mHK$262.5mHK$357.6mHK$344.2mHK$456.9mHK$138.8mHK$459.8m
Shareholders' equityHK$3.03bnHK$3.00bnHK$3.01bnHK$2.98bnHK$3.14bnHK$3.24bnHK$3.24bnHK$3.42bn

Financial ratios

Data as of 1 Nov 2026

FY2025FY2024FY2023FY2022FY2021FY2020FY2000FY1999
Gross margin19.5%26.6%27.4%27.0%31.8%26.6%——
Operating margin4.4%4.9%-5.0%7.2%6.6%-21.7%——
Net margin0.8%-11.1%-10.6%1.0%1.5%-26.3%——
Return on equity0.5%-6.8%-6.0%0.4%0.6%-7.4%——
Return on assets0.4%-4.9%-4.3%0.3%0.5%-6.1%——
Free cash flow yield14.9%25.7%24.0%5.7%15.6%6.1%——
Revenue growth-2.6%0.0%19.4%3.5%38.8%-5.3%——
Earnings growth-107.1%4.9%-1370.3%-30.5%-107.8%-2771.7%——
Current ratio3.64x3.19x3.25x3.90x5.64x6.34x——
Debt to equity0.04x0.10x0.12x0.11x0.02x0.02x——
Equity ratio75.8%72.1%72.0%73.5%81.5%83.2%——
Interest coverage6.84x4.42x-3.93x8.67x25.00x-43.90x——
R&D as a share of sales——————0.3%0.2%
Buybacks as a share of market value0.0%0.0%9.1%0.9%0.0%0.0%——

Growth per year

Compound annual rate

3 years5 years10 years
Revenue5.2%10.8%4.7%
Operating income72.6%—2.0%
Net income-2.0%—-25.0%

Average margins

Over each period

1 year3 years5 years10 years
Gross margin23.1%25.1%26.3%29.2%
Operating margin4.7%4.1%0.3%3.3%
Net margin-5.2%-5.3%-6.6%-2.3%

Valuation history

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Price to earnings117.8-8.2-11.3185.3150.4-18.4492.381.1-48.2152.8
Price to sales0.90.91.21.82.24.84.64.64.79.6

Dividends and splits

Per share, in the currency the company pays

Paid for 4 years. Last went ex-dividend on 24 Jun 2026.

FY2026FY2025FY2024FY2023FY2022FY2019FY2017FY2016
Paid in the year0.0020.0010.0010.0010.0020.0030.0030.01
  • 5-for-1 split · 28 May 2014
  • 100-to-1 reverse split · 25 May 2009
  • 3-for-1 split · 19 Jul 2007

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.